Dr. Dionysios Neofytos is an Attending Physician at the Division of Infectious Diseases, Transplant Infectious Disease Service, University Hospital of Geneva, Geneva, Switzerland. He completed his Master of Science in Public Health at the Thomas Jefferson University, Philadelphia, USA and his training in infectious diseases and internal medicine at the Thomas Jefferson University, Philadelphia and Newton-Wellesley Hospital, Boston, USA, respectively. Upon completion of training, he joined the School of Medicine, John Hopkins University and Memorial Sloan Kettering Cancer Center – Cornell University as an Assistant Professor and Attending Physician before joining the University of Hospital Geneva. He is actively involved in clinical research in the field of invasive fungal infections in immunocompromised hosts, presenting his work at international scientific meetings and conferences and has published numerous peer-reviewed articles and books in the field of infectious diseases and hematopoietic stem cell transplantation.
Dr Kim Yeoh, MBBS, is an advanced trainee in Infectious Diseases at the Department of Microbiology at The Royal Melbourne Hospital in Melbourne, Victoria, Australia and is an honorary clinical fellow at the Department of Infectious Diseases at The University of Melbourne at The Peter Doherty Institute for Infection and Immunity in Melbourne, Victoria, Australia.
Dr. Yeoh has a wide range of interests in infectious diseases including public health, infectious diseases in vulnerable and marginalized populations, antimicrobial stewardship, and infectious diseases in complex medical and surgical patients. After completion of her medical degree at The University of Melbourne, Dr. Yeoh spent time over 5 years working in Rwanda, Malawi and Zimbabwe, teaching within and coordinating the Specialists Without Borders medical education program for local doctors and medical students. Here she developed a passion for infectious diseases in resource poor settings. On returning to Australia, she further developed an interest in the management of infectious diseases in marginalized populations including refugees, and is actively involved in research in these areas. She hopes to continue to make a contribution to this area of work through her clinical practice, as well as through ongoing translational research in clinical infectious diseases and public health.
Cornelia Lass-Flörl is the Director of the Institute of Hygiene and Medical Microbiology of the Department of Hygiene, Microbiology and Social Medicine at the Medical University of Innsbruck, Austria. She is Fellow of the American Academy of Microbiology, of the European Society of Clinical Microbiology and Infectious Diseases, of the European Confederation of Medical Mycology and of the Infectious Diseases Society of America. She is a member of the Subcommittee on Antifungal Susceptibility Testing of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the European Committee for Antimicrobial Susceptibility Testing (EUCAST). Professor Lass-Flörl has authored several journal articles, abstracts, and book chapters. In 2020 she was placed on Clarivate Analytics’ list of highly cited researchers worldwide. Her teaching and clinical service responsibilities focus on the diagnosis of fungal infections in severely immunocompromised patients. Her research interests include both clinical investigation and advances in basic medical microbiological science, with special interests in the epidemiology, diagnosis, prevention and therapy of fungal infections.
Frédéric Lamoth is a Swiss medical doctor with board certification in internal medicine, infectious diseases and clinical microbiology. After a post-doctoral fellowship at Duke University (Durham, NC), he is currently working at the University Hospital of Lausanne (Switzerland). His research focuses on mechanisms of antifungal resistance, and diagnostic and therapeutic approaches of invasive fungal infections.
Allogeneic hematopoietic cell transplant recipient with acute myeloid leukemia and multiple myeloma who underwent cytarabine and daunorubicin (7+3) induction chemotherapy followed by cytarabine (HiDAC) consolidation, post fludarabine, melphalan and thymoglobulin conditioning regimen, with failure to engraft, requiring autologous stem cell rescue and buffy coat and granulocyte transfusions, eventually presenting with persistent neutropenic fever and positive blood cultures.
Transplant Infectious Disease
740 Notre-Dame Ouest
Montréal, QC, H3C 3X6